Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic

Joint effort to leverage existing collaboration and non-dilutive grants to advance development of proprietary Treg exosome technology towards a first-in-human clinical study, continue work on validating biomarkers in a variety of neurodegenerative diseases, and explore novel synergistic drug combinations with COYA 301 (proprietary Low Dose Interleukin-2, or LD IL-2)

On June 20, 2024, Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announced the expansion of its research collaboration with the Houston Methodist Research Institute (HMRI) through a sponsored research agreement (SRA) covering multiple initiatives. The development and production of exosomes from patients’ regulatory T cells will be funded by the Johnson Center for Cellular Therapeutics with participation of the SRA from Coya to Dr. Stanley Appel, Director of the Johnson Center and Chair of Coya’s Scientific Advisory Board. Coya and HMRI will advance the development of multiple patented modalities of exosomes, including full characterization of the nanovesicles, and GMP manufacturing to enable a first-in-human academic clinical study.

Login Or Register To Read Full Story